Health Condition 1: H401- Open-angle glaucoma Health Condition 2: null- Open-Angle Glaucoma or Ocular Hypertension
Conditions
Interventions
Intervention1: Brinzolamide 10mg in combination with Timolol Maleate 5mg Ophthalmic Suspension: One drop in the conjunctival sac of the affected eye(s) twice daily for 12 weeks
Control Intervention1:
Sponsors
Ajanta Pharma Ltd
Eligibility
Inclusion criteria
Inclusion criteria: 1.Patient having clinical diagnosis of ocular hypertension. 2.Freshly diagnosed patients of open angle glaucoma or ocular hypertension, Patients who are previously diagnosed and on treatment for open angle glaucoma or ocular hypertension will undergo washout period, Meiotic (7 days), Alpha Agonist and Alpha/beta agonist (14 days),β antagonist and prostaglandin analogs (28 days). 3.Subject with History of discontinued Carbonic anhydrase inhibitor of 2 months back. 4.Availability of subjects for the entire study period and willingness to adhere to protocol requirements as evidenced by written informed consent.
Exclusion criteria
Exclusion criteria: 1.Ocular trauma or intraocular surgery within the past 6 months. 2.Ocular infection, inflammation, or laser surgery within the past 3 months. 3.Chronic, recurrent or severe inflammatory eye disease 4.Central cornea thickness 620 mm, as measured by pachymetry, in either eye 5.Shaffer angle grade less than 2 in either eye (range, 0 [complete or partial closure] to 3 [wide open angle, more thab 20]), as measured by Gonioscopy. 6.Severe central visual field loss in either eye measured by Perimetry. 7.Clinically significant or progressive retinal disease. 8.Best-corrected visual acuity worse than 0.6 logMAR (Best Corrected VA score worse than 55 ETDRS letters (20/80 Snellen equivalent)) 9.Other ocular pathology (including severe dry eye) that may preclude the administration of an alpha-adrenergic agonist and/or a topical CAI. 10.A history of hypersensitivity to brinzolamide and other sulphonamides, timolol, or any other component of the medication. 11.Patients suffering from bronchial asthma, a history of bronchial asthma, or severe chronic obstructive pulmonary disease. 12.Patients suffering from sinus bradycardia, second or third degree atrioventricular block, overt cardiac failure, or cardiogenic shock. 13.Patients suffering from severe allergic rhinitis and bronchial hyperreactivity. 14.Patients suffering from severe renal impairment (see Hepatic / Renal Impairment). 15.Patients who have participated in other clinical studies within 3 months. 16.Any condition which are likely to hinder the compliance with the protocol. 17.Patients should not take other topical or oral beta-blockers during the study period. 18.Patients with broken rear lens capsule or anterior eye lenses or in patients with known risk factors for cystoid macular edema or iritis / uveitis. 19.Patients who are scheduled to undergo surgery of the opposite eye during the study period. 20.Patients who are required to wear contact lens during the study period. 21.Significant visual field loss or evidence of progressive visual field loss within the last year. 22.Patients with recent use of high-dose (1 gm daily) salicylate therapy 23.Females of childbearing potential if pregnant, lactating, or not using highly effective birth control measures. 24.Cup/disc ratio greater than 0.80 25.History or current evidence of severe illness or any other conditions which would make the subject, in the opinion of the Investigator, unsuitablefor the study. 26.Systemic administration of corticosteroids or immunosuppressive agents and local injection of corticosteroids in the eyes.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| IOP (Intraocular pressure) Measurement by Goldmann Applanation TonometryTimepoint: Day 1, 2nd week, 6th week, 9th week, 12th week | — |
Secondary
| Measure | Time frame |
|---|---|
| Eye pain, Eye redness, multicolored halos and headache will be graded by four point scale by the physicianTimepoint: Day 1, 2nd week, 6th week, 9th week, 12th week | — |
Countries
India
Contacts
Public ContactDr Shailesh Singh
Ajanta Pharma Ltd
Outcome results
None listed